Watch VelacurTM in Action at Liver Connect 2021

If you’re ready to transform your liver practice, we’re ready to show you how.

Discover how fast, accurate and easy VelacurTM is to assess liver health at the inaugural Liver Connect conference, April 16-17, 2021, hosted by the Chronic Liver Disease Foundation. Visit our in-person booth for live demos of Velacur, the first handheld 3D liver health assessment solution.

Developed by Sonic Incytes Medical Corp., VelacurTM is a breakthrough, point of care ultrasound solution that is redefining the standard of care for chronic liver disease. With diagnostic accuracy comparable to MRI, VelacurTM combines the principles of MRI with handheld ultrasound to quantify liver disease with greater accuracy and reliability than the current standard of care.

Interested in a private demo? Send us your request.

Follow us on LinkedInTwitter, and YouTube, and subscribe to our e-newsletter below.

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.

Julia PinterMarketing Director

Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.